Three of our portfolio companies (@CombatCancer @LightpointMed
and @entiahealth) named by Coutts as "#medtech marvels supporting the NHS"
Coutts backs med-tech marvels supporting NHS
Meet four of the firms forging the future of health care with help from our clients
www.coutts.com
To register for this Friday's webinar (5-6 UK) click on the Eventbrite link
#HIVEC #BCGUnresponsive
HIVEC for BCG Unresponsive
Find out more about HIVEC in BCG Unresponsive Patients with Clinical Discussion and Live Q&A. EAU20 Presented Data.
www.eventbrite.co.uk
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
@cordekroon @HUReinaSofia @ESSOnews @operarelcancer @SWexner @DeliaCortesGuir @FarazKh65499316 @dr_mohammadyami @AndreasBrandl8 @annafagottimd Closed system with CO2 agitation system @CombatCancer @jansenaxel is an option for drug distribution
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.
Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD
https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
@CombatCancer #HIPEC Don't forget to register to join Combat and Dr Alvaro-Arjona-Sanchez later today to find out more.
https://www.urotoday.com/conference-highlights/aua-2020/aua-2020-bladder-cancer/122466-aua-2020-bcg-vs-chemohyperthermia-with-mitomycin-c-for-high-risk-non-muscle-invasive-bladder-carcinoma-preliminary-results-of-hivec-hr-randomized-clinical-trial.html via @urotoday
Many thanks @urotoday for covering our trial data https://twitter.com/urotoday/status/1276923364402225152
#BCG vs chemohyperthermia with mitomycin C for high-risk #NMIBC. Preliminary results of HIVEC-HR randomized clinical trial presented by @DrFelixGuerrero @Urologia12. #AUAlive written coverage by @zklaassen_md @GACancerCenter on UroToday > https://bit.ly/384fw6I @AmerUrological
#HIPEC #Laparoscopic #SurgicalOncology @CombatCancer Join Combat and Consultant Surgeon Dr Alvaro-Arjona-Sanchez to find out more about Laparoscopic HIPEC experience and results. Register for online event https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
Don't forget to register for tomorrow's clinical discussion on HIVEC-R, look forward to seeing you and sharing this data that was selected for AUA20 #HIVEC
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
@Yormigjgv @DrFelixGuerrero @smumexico @UroTratamiento @Urologia12 Webinar:
Inscripción
ID de reunión: 915 9289 1390
Welcome! You are invited to join a webinar: Evaluación Clínica de Quimioterapia Térmica para Cáncer de Vejiga: Ponencia AUA 2020. After registering, you will receive a confirmation email about joining the webinar.
Ponente: Dr. Felix Guerrero Títular de la Unidad de Uroncología del Hospital Universitario 12 de Octubre, Madrid, España. Jefe la Unidad de Cáncer...
zoom.us
@CombatCancer #HIVEC Neo-Adjuvant HIVEC shows over 60% complete response and better RFS in preliminary trial result. Abstract accepted for AUA20, follow link to see full abstract https://bit.ly/2W2bA1Q
Combat is proud to be sponsoring the Global Congress on Bladder Cancer on the 20th and 21st of September 2018 in Madrid. More Clinical data on HIVEC treatments will be presented during the meeting. For more information see click here or visit us on stand.
